Healthcare / Wellness Services / Traditional Chinese Medicine / Women's Health
Strategic Profile
Charming Medical generated $6.22 million in revenue in fiscal year 2025, representing 3.43% growth compared to the prior year. The company targets women's health issues including menstrual irregularities, hormonal imbalance, and postpartum recovery, leveraging a growing market interest in TCM-inspired wellness solutions with product diversification across services, supplements, and beauty products.
Cyborg Score Rationale
MCTA shares more than doubled from their $4.00 IPO price in their NASDAQ debut, indicating strong initial market interest. However, limited operational scale (4 wellness centers, <$7M annual revenue) and recent litigation announcement present execution and legal risks, offsetting the strategic appeal of the TCM-wellness segment.
Top Insights
The company intends to use IPO proceeds for expanding its business and geographic coverage, potential strategic investments and acquisitions, and research and development
Strong NASDAQ debut performance (more than 100% first-day jump) suggests investor appetite for TCM wellness and women's health services
Services are designed to meet diverse health improvement needs including alleviating premenstrual syndrome, menstrual irregularities, dysmenorrhea, leukorrhea, pelvic inflammatory disease, menopausal care, and breast health
Earnings increased 54.16% year-over-year to $1.20 million, demonstrating profitability and improving unit economics
Named Competitors
Traditional beauty and wellness services — Conventional postpartum care and beauty centers
TCM practitioners and clinics — Direct acupuncture and herbal medicine services
Supplement and skincare products — Direct-to-consumer women's health and beauty products
Recent Developments
(October 2025) Commenced trading on NASDAQ under ticker MCTA following IPO priced at $4.00 per share
(October 2025) Full exercise of over-allotment option, raising additional capital beyond initial $6.4 million IPO proceeds
(January 2026) Wolf Haldenstein Adler Freeman & Herz LLP issued class action reminder for securities claims with February 17, 2026 lead plaintiff deadline
Open the full interactive Charming Medical Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.